Difference between revisions of "Vindesine (Eldisine)"

Revision as of 17:42, 25 July 2017

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.^[1]^[2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Not approved by the FDA. Approved for use in some countries e.g. Britain, South Africa.

Also known as

Desacetylvinblastine amide, DAVA, DVA, Eldesine, Fildesin, or VDS.

References

[insert-1] 1.0 ^1.1 Vindesine (Eldisine) package insert

[2] Vindesine (Eldisine) package insert (locally hosted backup)

[3] Vindesine (Eldisine) patient information at Macmillan Cancer Support

[4] Vindesine (Eldisine) patient information at Genus Pharmaceuticals

[5] Vindesine (Eldisine) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

@@ Line 30: / Line 30: @@
 [[Category:Drug index]]
 [[Category:Chemotherapy]]
-[[Category:Intravenous chemotherapy]]
+[[Category:Intravenous medications]]
 [[Category:Vesicant chemotherapy]]